Canaccord analyst Whitney Ijem last night initiated coverage of Arcturus Therapeutics with a Buy rating and $81 price target. In the genetic medicine space, many companies focus efforts on either the delivery vehicle or the cargo, but Arcturus has done both, the analyst tells investors in a research note. The firm says the company has developed proprietary and differentiated LNP delivery technology, as well as novel mRNA cargos allowing for options based on the application. It say Arcturus has a pipeline of medicines across a range of indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARCT:
- Arcturus Therapeutics price target raised to $60 from $51 at H.C. Wainwright
- CSL’s and Arcturus Therapeutics’ mRNA vaccine for COVID approved in Japan
- Arcturus Therapeutics receives Orphan Drug Designation for ARCT-032 from FDA
- Arcturus Therapeutics treatment of cystic fibrosis granted orphan status
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com